Just last week BioLineRx, a biopharmaceutical development company announced successful pre-clinical testing of a potentially revolutionary treatment for celiac disease. This new treatment may help celiac disease patients reduce their gluten toxins to create an overall healthy body for all celiac disease patients.
Jerusalem, Israel – February 21, 2012 – BioLineRx (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced the publication of pre-clinical results demonstrating that BL-7010, an orally available treatment for celiac disease, reduces gluten toxicity (the negative effect of gluten on the patient’s body). The research was published in the February edition of Gastroenterology.
The findings indicate that BL-7010 (previously called P(HEMA-co-SS)) reduces digestion of wheat gluten, thereby decreasing its Read More »